Contribution of tumoral and host solute carriers to clinical drug response

Drug Resistance Updates

Volumn 15, Issue 1-2, 2012, Pages 5-20

  Sprowl, Jason A ^a   Mikkelsen, Torben S ^b   Giovinazzo, Hugh ^a,c   Sparreboom, Alex ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Anticancer drugs; Drug disposition; Pharmacodynamics; Solute carriers

Indexed keywords

BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; CLADRIBINE; CYTARABINE; DASATINIB; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IMATINIB; IRINOTECAN; LAPATINIB; MELPHALAN; MERCAPTOPURINE; MESNA; METHOTREXATE; MITOXANTRONE; NILOTINIB; OXALIPLATIN; TOPOTECAN; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG DISPOSITION; DRUG EFFICACY; DRUG UPTAKE; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; HEAD AND NECK CANCER; HEARING LOSS; HUMAN; LUNG CANCER; LYMPHOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; THROMBOCYTOPENIA;

EID: 84860652454     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2012.01.009     Document Type: Article

References (329)

1. T. Abe, M. Kakyo, T. Tokui, R. Nakagomi, T. Nishio, D. Nakai, H. Nomura, M. Unno, M. Suzuki, T. Naitoh, S. Matsuno, and H. Yawo Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1 J. Biol. Chem. 274 1999 17159 17163
2. T. Abe, M. Unno, T. Onogawa, T. Tokui, T.N. Kondo, R. Nakagomi, H. Adachi, K. Fujiwara, M. Okabe, T. Suzuki, K. Nunoki, E. Sato, M. Kakyo, T. Nishio, J. Sugita, N. Asano, M. Tanemoto, M. Seki, F. Date, K. Ono, Y. Kondo, K. Shiiba, M. Suzuki, H. Ohtani, T. Shimosegawa, K. Iinuma, H. Nagura, S. Ito, and S. Matsuno LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers Gastroenterology 120 2001 1689 1699
3. S. Agarwal, R. Sane, J.L. Gallardo, J.R. Ohlfest, and W.F. Elmquist Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux J. Pharmacol. Exp. Ther. 334 2010 147 155
4. S. Agarwal, R. Sane, J.R. Ohlfest, and W.F. Elmquist The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain J. Pharmacol. Exp. Ther. 336 2011 223 233
5. C. Aghajanian, D.S. Dizon, P. Sabbatini, J.J. Raizer, J. Dupont, and D.R. Spriggs Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer J. Clin. Oncol. 23 2005 5943 5949
6. C.M. Anderson, and D.T. Thwaites Hijacking solute carriers for proton-coupled drug transport Physiology. 25 2010 364 377
7. M. Aouida, and D. Ramotar A new twist in cellular resistance to the anticancer drug bleomycin-A5 Curr. Drug Metab. 11 2010 595 602
8. A. Ardizzoni, L. Boni, M. Tiseo, F.V. Fossella, J.H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, D. Bisset, and R. Rosell Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis J. Natl. Cancer Inst. 99 2007 847 857
9. B.L. Asselin, M. Devidas, C. Wang, J. Pullen, M.J. Borowitz, R. Hutchison, S.E. Lipshultz, and B.M. Camitta Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404) Blood 118 2011 874 883
10. I. Badagnani, R.A. Castro, T.R. Taylor, C.M. Brett, C.C. Huang, D. Stryke, M. Kawamoto, S.J. Johns, T.E. Ferrin, E.J. Carlson, E.G. Burchard, and K.M. Giacomini Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants J. Pharmacol. Exp. Ther. 318 2006 521 529
11. I. Badagnani, W. Chan, R.A. Castro, C.M. Brett, C.C. Huang, D. Stryke, M. Kawamoto, S.J. Johns, T.E. Ferrin, E.J. Carlson, E.G. Burchard, and K.M. Giacomini Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3) Pharmacogenomics J. 5 2005 157 165
12. S.D. Baker, and S. Hu Pharmacokinetic considerations for new targeted therapies Clin. Pharmacol. Ther. 85 2009 208 211
13. S.D. Baker, A. Sparreboom, and J. Verweij Clinical pharmacokinetics of docetaxel: recent developments Clin. Pharmacokinet. 45 2006 235 252
14. S.D. Baker, J. Verweij, G.A. Cusatis, R.H. van Schaik, S. Marsh, S.J. Orwick, R.M. Franke, S. Hu, E.G. Schuetz, V. Lamba, W.A. Messersmith, A.C. Wolff, M.A. Carducci, and A. Sparreboom Pharmacogenetic pathway analysis of docetaxel elimination Clin. Pharmacol. Ther. 85 2009 155 163
15. T. Bansal, G. Mishra, M. Jaggi, R.K. Khar, and S. Talegaonkar Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats Eur. J. Pharm. Sci. 36 2009 580 590
16. V.M. Belkov, E.Y. Krynetski, J.D. Schuetz, Y. Yanishevski, E. Masson, S. Mathew, S. Raimondi, C.H. Pui, M.V. Relling, and W.E. Evans Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation Blood 93 1999 1643 1650
17. G.L. Beretta, L. Gatti, S. Tinelli, E. Corna, D. Colangelo, F. Zunino, and P. Perego Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells Biochem. Pharmacol. 68 2004 283 291
18. Y. Bessho, T. Oguri, H. Achiwa, H. Muramatsu, H. Maeda, T. Niimi, S. Sato, and R. Ueda Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer Cancer Sci. 97 2006 192 198
19. S.P. Binks, and M. Dobrota Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine Biochem. Pharmacol. 40 1990 1329 1336
20. B.G. Blair, C.A. Larson, R. Safaei, and S.B. Howell Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin Clin. Cancer Res. 15 2009 4312 4321
21. C.D. Blanke, C. Rankin, G.D. Demetri, C.W. Ryan, M. von Mehren, R.S. Benjamin, A.K. Raymond, V.H. Bramwell, L.H. Baker, R.G. Maki, M. Tanaka, J.R. Hecht, M.C. Heinrich, C.D. Fletcher, J.J. Crowley, and E.C. Borden Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J. Clin. Oncol. 26 2008 626 632
22. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J. Natl. Cancer Inst. 92 2000 1295 1302
23. P. Breedveld, D. Pluim, G. Cipriani, F. Dahlhaus, M.A. van Eijndhoven, C.J. de Wolf, A. Kuil, J.H. Beijnen, G.L. Scheffer, G. Jansen, P. Borst, and J.H. Schellens The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models Mol. Pharmacol. 71 2007 240 249
24. O. Briz, M.A. Serrano, N. Rebollo, B. Hagenbuch, P.J. Meier, H. Koepsell, and J.J. Marin Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells Mol. Pharmacol. 61 2002 853 860
25. E. Buchdunger, J. Zimmermann, H. Mett, T. Meyer, M. Muller, B.J. Druker, and N.B. Lydon Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res. 56 1996 100 104
26. T.D. Buitenkamp, R.A. Mathot, V. de Haas, R. Pieters, and C.M. Zwaan Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia Haematologica 95 2010 1106 1113
27. H. Burger, H. van Tol, A.W. Boersma, M. Brok, E.A. Wiemer, G. Stoter, and K. Nooter Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump Blood 104 2004 2940 2942
28. H. Burger, A. Zoumaro-Djayoon, A.W. Boersma, J. Helleman, E.M. Berns, R.H. Mathijssen, W.J. Loos, and E.A. Wiemer Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) Br. J. Pharmacol. 159 2010 898 908
29. W.L. Burland, W.A. Duncan, T. Hesselbo, J.G. Mills, P.C. Sharpe, S.J. Haggie, and J.H. Wyllie Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man Br. J. Clin. Pharmacol. 2 1975 481 486
30. L. Candeil, I. Gourdier, D. Peyron, N. Vezzio, V. Copois, F. Bibeau, B. Orsetti, G.L. Scheffer, M. Ychou, Q.A. Khan, Y. Pommier, B. Pau, P. Martineau, and M. Del Rio ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases Int. J. Cancer 109 2004 848 854
31. J.W. Catto, and F.C. Hamdy Targeting chemotherapy to advanced bladder cancer patients most likely to benefit Future Oncol. 6 2010 193 196
32. S.H. Cha, T. Sekine, J.I. Fukushima, Y. Kanai, Y. Kobayashi, T. Goya, and H. Endou Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney Mol. Pharmacol. 59 2001 1277 1286
33. Y. Chen, K. Teranishi, S. Li, S.W. Yee, S. Hesselson, D. Stryke, S.J. Johns, T.E. Ferrin, P. Kwok, and K.M. Giacomini Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function Pharmacogenomics J. 9 2009 127 136
34. Z.S. Chen, T. Furukawa, T. Sumizawa, K. Ono, K. Ueda, K. Seto, and S.I. Akiyama ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P Mol. Pharmacol. 55 1999 921 928
35. S.C. Chew, O. Singh, X. Chen, R.D. Ramasamy, T. Kulkarni, E.J. Lee, E.H. Tan, W.T. Lim, and B. Chowbay The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients Cancer Chemother. Pharmacol. 67 2011 1471 1478
36. I. Chitapanarux, E. Tharavichitkul, V. Lorvidhaya, P. Sittitrai, and T. Pattarasakulchai Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer Biomed. Imaging. Interv. J. 6 2010 e23
37. M.K. Choi, and I.S. Song Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences Drug Metab. Pharmacokinet. 23 2008 243 253
38. X.Y. Chu, Y. Kato, K. Niinuma, K.I. Sudo, H. Hakusui, and Y. Sugiyama Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats J. Pharmacol. Exp. Ther. 281 1997 304 314
39. X.Y. Chu, Y. Kato, and Y. Sugiyama Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats Drug Metab. Dispos. 27 1999 440 441
40. G. Ciarimboli Organic cation transporters Xenobiotica. 38 2008 936 971
41. G. Ciarimboli, D. Deuster, A. Knief, M. Sperling, M. Holtkamp, B. Edemir, H. Pavenstadt, C. Lanvers-Kaminsky, A. Am Zehnhoff-Dinnesen, A.H. Schinkel, H. Koepsell, H. Jurgens, and E. Schlatter Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions Am. J. Pathol. 176 2010 1169 1180
42. G. Ciarimboli, S.K. Holle, B. Vollenbrocker, Y. Hagos, S. Reuter, G. Burckhardt, S. Bierer, E. Herrmann, H. Pavenstadt, R. Rossi, R. Kleta, and E. Schlatter New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2 Mol. Pharmacol. 8 2011 270 279
43. G. Ciarimboli, T. Ludwig, D. Lang, H. Pavenstadt, H. Koepsell, H.J. Piechota, J. Haier, U. Jaehde, J. Zisowsky, and E. Schlatter Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2 Am. J. Pathol. 167 2005 1477 1484
44. Collins, I.M., Roberts-Thomson, R., Faulkner, D., Rischin, D., Friedlander, M. and Mileshkin, L., 2011. Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls. Int. J. Gynecol. Cancer.
45. Crossman, L.C., Druker, B.J., Deininger, M.W., Pirmohamed, M., Wang, L. and Clark, R.E., 2005. hOCT 1 and resistance to imatinib. Blood 106, 1133-1134; author reply 1134.
46. Y. Cui, J. Konig, J.K. Buchholz, H. Spring, I. Leier, and D. Keppler Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55 1999 929 937
47. Y. Cui, J. Konig, A.T. Nies, M. Pfannschmidt, M. Hergt, W.W. Franke, W. Alt, R. Moll, and D. Keppler Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma Lab. Invest. 83 2003 527 538
48. M.J. Cutler, B.L. Urquhart, T.J. Velenosi, H.E. Meyer Zu Schwabedissen, G.K. Dresser, B.F. Leake, R.G. Tirona, R.B. Kim, and D.J. Freeman In Vitro and In Vivo Assessment of Renal Drug Transporters in the Disposition of Mesna and Dimesna J. Clin. Pharmacol 2011
49. A.M. Davies, K. Chansky, P.N. Lara Jr., P.H. Gumerlock, J. Crowley, K.S. Albain, S.J. Vogel, and D.R. Gandara Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339) J. Thorac. Oncol. 4 2009 87 92
50. F.A. de Jong, M.J. de Jonge, J. Verweij, and R.H. Mathijssen Role of pharmacogenetics in irinotecan therapy Cancer Lett. 234 2006 90 106
51. F.A. de Jong, T.J. Scott-Horton, D.L. Kroetz, H.L. McLeod, L.E. Friberg, R.H. Mathijssen, J. Verweij, S. Marsh, and A. Sparreboom Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein Clin. Pharmacol. Ther. 81 2007 42 49
52. F.A. de Jong, and J. Verweij Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors Expert Rev. Anticancer Ther. 3 2003 757 766
53. R. de Jonge, J.H. Hooijberg, B.D. van Zelst, G. Jansen, C.H. van Zantwijk, G.J. Kaspers, G.J. Peters, Y. Ravindranath, R. Pieters, and J. Lindemans Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia Blood 106 2005 717 720
54. C. de Wolf, R. Jansen, H. Yamaguchi, M. de Haas, K. van de Wetering, J. Wijnholds, J. Beijnen, and P. Borst Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Mol. Cancer Ther. 7 2008 3092 3102
55. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, P.J. Roberts, M.C. Heinrich, D.A. Tuveson, S. Singer, M. Janicek, J.A. Fletcher, S.G. Silverman, S.L. Silberman, R. Capdeville, B. Kiese, B. Peng, S. Dimitrijevic, B.J. Druker, C. Corless, C.D. Fletcher, and H. Joensuu Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
56. G.D. Demetri, Y. Wang, E. Wehrle, A. Racine, Z. Nikolova, C.D. Blanke, H. Joensuu, and M. von Mehren Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors J. Clin. Oncol. 27 2009 3141 3147
57. K.H. Dixon, B.C. Lanpher, J. Chiu, K. Kelley, and K.H. Cowan A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells J. Biol. Chem. 269 1994 17 20
58. P.D. Dobson, and D.B. Kell Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov. 7 2008 205 220
59. P.D. Dobson, K. Lanthaler, S.G. Oliver, and D.B. Kell Implications of the dominant role of transporters in drug uptake by cells Curr. Top. Med. Chem. 9 2009 163 181
60. M. Dohse, C. Scharenberg, S. Shukla, R.W. Robey, T. Volkmann, J.F. Deeken, C. Brendel, S.V. Ambudkar, A. Neubauer, and S.E. Bates Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib Drug Metab. Dispos. 38 2010 1371 1380
61. B.J. Druker Translation of the Philadelphia chromosome into therapy for CML Blood 112 2008 4808 4817
62. B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M.W. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone, F. Cervantes, A. Hochhaus, B.L. Powell, J.L. Gabrilove, P. Rousselot, J. Reiffers, J.J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J.L. Nielsen, J.P. Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, and R.A. Larson Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N. Engl. J. Med. 355 2006 2408 2417
63. K. Eechoute, R.M. Franke, W.J. Loos, L.A. Scherkenbach, I. Boere, J. Verweij, H. Gurney, R.B. Kim, R.G. Tirona, R.H. Mathijssen, and A. Sparreboom Environmental and genetic factors affecting transport of imatinib by OATP1A2 Clin. Pharmacol. Ther. 89 2011 816 820
64. K. Eechoute, A. Sparreboom, H. Burger, R.M. Franke, G. Schiavon, J. Verweij, W.J. Loos, E.A. Wiemer, and R.H. Mathijssen Drug transporters and imatinib treatment: implications for clinical practice Clin. Cancer Res. 17 2011 406 415
65. A.A. El-Sheikh, J.J. van den Heuvel, J.B. Koenderink, and F.G. Russel Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport J. Pharmacol. Exp. Ther. 320 2007 229 235
66. Y. Endo, T. Obata, D. Murata, M. Ito, K. Sakamoto, M. Fukushima, Y. Yamasaki, Y. Yamada, N. Natsume, and T. Sasaki Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides Cancer Sci. 98 2007 1633 1637
67. J.R. Engler, A. Frede, V. Saunders, A. Zannettino, D.L. White, and T.P. Hughes The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells Blood 116 2010 2776 2778
68. J.R. Engler, T.P. Hughes, and D.L. White OCT-1 as a determinant of response to antileukemic treatment Clin. Pharmacol. Ther. 89 2011 608 611
69. S. Farber, and L.K. Diamond Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid N. Engl. J. Med. 238 1948 787 793
70. K.K. Filipski, W.J. Loos, J. Verweij, and A. Sparreboom Interaction of Cisplatin with the human organic cation transporter 2 Clin Cancer Res. 14 2008 3875 3880
71. K.K. Filipski, R.H. Mathijssen, T.S. Mikkelsen, A.H. Schinkel, and A. Sparreboom Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity Clin. Pharmacol. Ther. 86 2009 396 402
72. G.A. Fischer Detective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells Biochem. Pharmacol. 11 1962 1233 1234
73. K.T. Flaherty, C. Lathia, R.F. Frye, L. Schuchter, M. Redlinger, M. Rosen, and P.J. O'Dwyer Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study Cancer Chemother. Pharmacol. 68 2011 1111 1118
74. W.F. Flintoff, H. Sadlish, R. Gorlick, R. Yang, and F.M. Williams Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas Biochim. Biophys. Acta 1690 2004 110 117
75. S.L. Forchap, M. Pirmohamed, and R.E. Clark Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis Leukemia 2011
76. A.K. Fotoohi, M. Lindqvist, C. Peterson, and F. Albertioni Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines Biochem. Biophys. Res. Commun. 343 2006 208 215
77. J.T. Fox, and P.J. Stover Folate-mediated one-carbon metabolism Vitam. Horm. 79 2008 1 44
78. N.Y. Frank, A. Margaryan, Y. Huang, T. Schatton, A.M. Waaga-Gasser, M. Gasser, M.H. Sayegh, W. Sadee, and M.H. Frank ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma Cancer Res. 65 2005 4320 4333
79. R.M. Franke, M.A. Carducci, M.A. Rudek, S.D. Baker, and A. Sparreboom Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer J. Clin. Oncol. 28 2010 4562 4567
80. R.M. Franke, A.M. Kosloske, C.S. Lancaster, K.K. Filipski, C. Hu, O. Zolk, R.H. Mathijssen, and A. Sparreboom Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase Clin. Cancer Res. 16 2010 4198 4206
81. G.R. Gale, C.R. Morris, L.M. Atkins, and A.B. Smith Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents Cancer Res. 33 1973 813 818
82. M.L. Garre, M.V. Relling, D. Kalwinsky, R. Dodge, W.R. Crom, M. Abromowitch, C.H. Pui, and W.E. Evans Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia J. Pediatr. 111 1987 606 612
83. Y. Ge, C.L. Haska, K. LaFiura, M. Devidas, S.B. Linda, M. Liu, R. Thomas, J.W. Taub, and L.H. Matherly Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group Clin. Cancer Res. 13 2007 451 457
84. K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K.M. Hillgren, K.A. Hoffmaster, T. Ishikawa, D. Keppler, R.B. Kim, C.A. Lee, M. Niemi, J.W. Polli, Y. Sugiyama, P.W. Swaan, J.A. Ware, S.H. Wright, S.W. Yee, M.J. Zamek-Gliszczynski, and L. Zhang Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
85. H. Glaeser, D.G. Bailey, G.K. Dresser, J.C. Gregor, U.I. Schwarz, J.S. McGrath, E. Jolicoeur, W. Lee, B.F. Leake, R.G. Tirona, and R.B. Kim Intestinal drug transporter expression and the impact of grapefruit juice in humans Clin. Pharmacol. Ther. 81 2007 362 370
86. R.M. Goldberg, D.J. Sargent, R.F. Morton, C.S. Fuchs, R.K. Ramanathan, S.K. Williamson, B.P. Findlay, H.C. Pitot, and S.R. Alberts A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J. Clin. Oncol. 22 2004 23 30
87. A. Goldin, S.R. Humphreys, N. Mantel, and J.M. Venditti Modification of treatment of schedules in the management of advanced mouse leukemia with amethopterin J. Natl. Cancer Inst. 17 1956 203 212
88. I.D. Goldman The characteristics of the membrane transport of amethopterin and the naturally occurring folates Ann. N. Y. Acad. Sci. 186 1971 400 422
89. I.D. Goldman, N.S. Lichtenstein, and V.T. Oliverio Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell J. Biol. Chem. 243 1968 5007 5017
90. E. Gonzalez-Haba, M.I. Garcia, L. Cortejoso, C. Lopez-Lillo, N. Barrueco, P. Garcia-Alfonso, S. Alvarez, J.L. Jimenez, M.L. Martin, M.A. Munoz-Fernandez, M. Sanjurjo, and L.A. Lopez-Fernandez ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients Pharmacogenomics 11 2010 1715 1723
91. V. Gorboulev, J.C. Ulzheimer, A. Akhoundova, I. Ulzheimer-Teuber, U. Karbach, S. Quester, C. Baumann, F. Lang, A.E. Busch, and H. Koepsell Cloning and characterization of two human polyspecific organic cation transporters DNA Cell Biol. 16 1997 871 881
92. R. Gorlick, E. Goker, T. Trippett, M. Waltham, D. Banerjee, and J.R. Bertino Intrinsic and acquired resistance to methotrexate in acute leukemia N. Engl. J. Med. 335 1996 1041 1048
93. K.A. Graham, J. Leithoff, I.R. Coe, D. Mowles, J.R. Mackey, J.D. Young, and C.E. Cass Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1 Nucleos. Nucleot. Nucl. 19 2000 415 434
94. J. Gregers, I.J. Christensen, K. Dalhoff, B. Lausen, H. Schroeder, S. Rosthoej, N. Carlsen, K. Schmiegelow, and C. Peterson The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number Blood 115 2010 4671 4677
95. D. Grundemann, V. Gorboulev, S. Gambaryan, M. Veyhl, and H. Koepsell Drug excretion mediated by a new prototype of polyspecific transporter Nature 372 1994 549 552
96. S. Guo, X. Zhang, L. Gan, C. Zhu, and Y. Gan Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2) J. Pharm. Pharmacol. 62 2010 973 984
97. Y. Guo, K. Kock, C.A. Ritter, Z.S. Chen, M. Grube, G. Jedlitschky, T. Illmer, M. Ayres, J.F. Beck, W. Siegmund, G. Ehninger, V. Gandhi, H.K. Kroemer, G.D. Kruh, and M. Schaich Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival Clin. Cancer Res. 15 2009 1762 1769
98. M. Gusella, F. Pasini, C. Bolzonella, S. Meneghetti, C. Barile, A. Bononi, S. Toso, D. Menon, G. Crepaldi, Y. Modena, L. Stievano, and R. Padrini Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours Br. J. Clin. Pharmacol. 71 2011 437 444
99. B. Hagenbuch Drug uptake systems in liver and kidney: a historic perspective Clin. Pharmacol. Ther. 87 2010 39 47
100. M.D. Hall, M. Okabe, D.W. Shen, X.J. Liang, and M.M. Gottesman The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy Annu. Rev. Pharmacol. Toxicol. 48 2008 495 535
101. S. Halwachs, C. Lakoma, I. Schafer, P. Seibel, and W. Honscha The antiepileptic drugs Phenobarbital and Carbamazepine reduce transport of methotrexate in rat choroid plexus by downregulation of the Reduced folate carrier Mol. Pharmacol. 80 2011 621 629
102. S. Halwachs, I. Schafer, P. Seibel, and W. Honscha Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity Leukemia. 23 2009 1087 1097
103. A. Hamada, H. Miyano, H. Watanabe, and H. Saito Interaction of imatinib mesilate with human P-glycoprotein J. Pharmacol. Exp. Ther. 307 2003 824 828
104. A. Hamada, T. Sissung, D.K. Price, R. Danesi, C.H. Chau, N. Sharifi, D. Venzon, K. Maeda, K. Nagao, A. Sparreboom, H. Mitsuya, W.L. Dahut, and W.D. Figg Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer Clin. Cancer Res. 14 2008 3312 3318
105. J.Y. Han, H.S. Lim, Y.K. Yoo, E.S. Shin, Y.H. Park, S.Y. Lee, J.E. Lee, D.H. Lee, H.T. Kim, and J.S. Lee Associations of ABCB1 ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 110 2007 138 147
106. Y.H. Han, D. Busler, Y. Hong, Y. Tian, C. Chen, and A.D. Rodrigues Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human kidney drug transporters Drug Metab. Dispos. 38 2010 1064 1071
107. A. Haouala, H. Rumpold, G. Untergasser, T. Buclin, H.B. Ris, N. Widmer, and L.A. Decosterd siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors Drug Metab. Lett. 4 2010 114 119
108. M.A. Hediger, M.F. Romero, J.B. Peng, A. Rolfs, H. Takanaga, and E.A. Bruford The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction Pflugers Archiv. 447 2004 465 468
109. M.C. Heinrich, C.L. Corless, C.D. Blanke, G.D. Demetri, H. Joensuu, P.J. Roberts, B.L. Eisenberg, M. von Mehren, C.D. Fletcher, K. Sandau, K. McDougall, W.B. Ou, C.J. Chen, and J.A. Fletcher Molecular correlates of imatinib resistance in gastrointestinal stromal tumors J. Clin. Oncol. 24 2006 4764 4774
110. J. Helleman, H. Burger, I.H. Hamelers, A.W. Boersma, A.I. de Kroon, G. Stoter, and K. Nooter Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter Cancer Biol. Ther. 5 2006 943 949
111. S.L. Hembruff, M.L. Laberge, D.J. Villeneuve, B. Guo, Z. Veitch, M. Cecchetto, and A.M. Parissenti Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance BMC Cancer. 8 2008 318
112. D.J. Higby, H.J. Wallace Jr., D.J. Albert, and J.F. Holland Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors Cancer. 33 1974 1215 1219
113. A.K. Holzer, and S.B. Howell The internalization and degradation of human copper transporter 1 following cisplatin exposure Cancer Res. 66 2006 10944 10952
114. A.K. Holzer, G.H. Manorek, and S.B. Howell Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin Mol. Pharmacol. 70 2006 1390 1394
115. E. Hopper-Borge, Z.S. Chen, I. Shchaveleva, M.G. Belinsky, and G.D. Kruh Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel Cancer Res. 64 2004 4927 4930
116. L. Horn, E.L. Castellanos, and D.H. Johnson Update on new drugs in small cell lung cancer Expert Opin. Investig. Drugs 20 2011 441 445
117. Z. Hou, S.E. Stapels, C.L. Haska, and L.H. Matherly Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods J. Biol. Chem. 280 2005 36206 36213
118. Z. Hou, J. Ye, C.L. Haska, and L.H. Matherly Transmembrane domains 4, 5, 7, 8, and 10 of the human reduced folate carrier are important structural or functional components of the transmembrane channel for folate substrates J. Biol. Chem. 281 2006 33588 33596
119. S.B. Howell, R. Safaei, C.A. Larson, and M.J. Sailor Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs Mol. Pharmacol. 77 2010 887 894
120. S. Hu, R.M. Franke, K.K. Filipski, C. Hu, S.J. Orwick, E.A. de Bruijn, H. Burger, S.D. Baker, and A. Sparreboom Interaction of imatinib with human organic ion carriers Clin. Cancer Res. 14 2008 3141 3148
121. Y. Huang, P. Anderle, K.J. Bussey, C. Barbacioru, U. Shankavaram, Z. Dai, W.C. Reinhold, A. Papp, J.N. Weinstein, and W. Sadee Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance Cancer Res. 64 2004 4294 4301
122. I. Hubeek, R.W. Stam, G.J. Peters, R. Broekhuizen, J.P. Meijerink, E.R. van Wering, B.E. Gibson, U. Creutzig, C.M. Zwaan, J. Cloos, D.J. Kuik, R. Pieters, and G.J. Kaspers The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia Br. J. Cancer 93 2005 1388 1394
123. M.T. Huisman, A.A. Chhatta, O. van Tellingen, J.H. Beijnen, and A.H. Schinkel MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid Int. J. Cancer 116 2005 824 829
124. J.S. Hulot, E. Villard, A. Maguy, V. Morel, L. Mir, I. Tostivint, D. William-Faltaos, C. Fernandez, S. Hatem, G. Deray, M. Komajda, V. Leblond, and P. Lechat A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination Pharmacogenet Genomics 15 2005 277 285
125. A. Ibrahim, S. Hirschfeld, M.H. Cohen, D.J. Griebel, G.A. Williams, and R. Pazdur FDA drug approval summaries: oxaliplatin Oncologist 9 2004 8 12
126. F. Innocenti, D.L. Kroetz, E. Schuetz, M.E. Dolan, J. Ramirez, M. Relling, P. Chen, S. Das, G.L. Rosner, and M.J. Ratain Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics J. Clin. Oncol. 27 2009 2604 2614
127. S. Ishida, J. Lee, D.J. Thiele, and I. Herskowitz Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals Proc. Natl. Acad. Sci. U. S. A. 99 2002 14298 14302
128. D. Iusuf, S.F. Teunissen, E. Wagenaar, H. Rosing, J.H. Beijnen, and A.H. Schinkel P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration J. Pharmacol. Exp. Ther. 337 2011 710 717
129. L. Iyer, J. Ramirez, D.R. Shepard, C.M. Bingham, D.K. Hossfeld, M.J. Ratain, and U. Mayer Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice Cancer Chemother. Pharmacol. 49 2002 336 341
130. E. Jacquemin, B. Hagenbuch, B. Stieger, A.W. Wolkoff, and P.J. Meier Expression cloning of a rat liver Na(+)-independent organic anion transporter Proc. Natl. Acad. Sci. U. S. A. 91 1994 133 137
131. D.D. Jandial, S. Farshchi-Heydari, C.A. Larson, G.I. Elliott, W.J. Wrasidlo, and S.B. Howell Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1 Clin. Cancer Res. 15 2009 553 560
132. H. Joensuu, C. Fletcher, S. Dimitrijevic, S. Silberman, P. Roberts, and G. Demetri Management of malignant gastrointestinal stromal tumours Lancet Oncol. 3 2002 655 664
133. N.N. Jong, T. Nakanishi, J.J. Liu, I. Tamai, and M.J. McKeage Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons J. Pharmacol. Exp. Ther. 338 2011 537 547
134. I. Judson, P. Ma, B. Peng, J. Verweij, A. Racine, E.D. di Paola, M. van Glabbeke, S. Dimitrijevic, M. Scurr, H. Dumez, and A. van Oosterom Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 55 2005 379 386
135. L. Kager Pharmacogenomics to improve childhood acute lymphoblastic
136. B.A. Kamen High-dose methotrexate: insecure rationale: take 2 J. Pediatr. Hematol. Oncol. 30 2008 639 640
137. B.A. Kamen, E. Rubin, J. Aisner, and E. Glatstein High-time chemotherapy or high time for low dose J. Clin. Oncol. 18 2000 2935 2937
138. H.M. Kantarjian, R.A. Larson, F. Guilhot, S.G. O'Brien, M. Mone, M. Rudoltz, T. Krahnke, J. Cortes, and B.J. Druker Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase Cancer 115 2009 551 560
139. N. Kartner, M. Shales, J.R. Riordan, and V. Ling Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein Cancer Res. 43 1983 4413 4419
140. R. Katayama, S. Koike, S. Sato, Y. Sugimoto, T. Tsuruo, and N. Fujita Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export Cancer Sci. 100 2009 2060 2068
141. H. Katsuda, M. Yamashita, H. Katsura, J. Yu, Y. Waki, N. Nagata, Y. Sai, and K. Miyamoto Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity Biol. Pharm. Bull. 33 2010 1867 1871
142. S. Kawabata, M. Oka, H. Soda, K. Shiozawa, K. Nakatomi, J. Tsurutani, Y. Nakamura, S. Doi, T. Kitazaki, K. Sugahara, Y. Yamada, S. Kamihira, and S. Kohno Expression and functional analyses of breast cancer resistance protein in lung cancer Clin. Cancer Res. 9 2003 3052 3057
143. T. Kawabe, Z.S. Chen, M. Wada, T. Uchiumi, M. Ono, S. Akiyama, and M. Kuwano Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2) FEBS Lett. 456 1999 327 331
144. D.A. Keefe, R.L. Capizzi, and S.A. Rudnick Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability Cancer Res. 42 1982 1641 1645
145. S.V. Keisner, and S.R. Shah Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma Drugs 71 2011 443 454
146. D.H. Kim, L. Sriharsha, W. Xu, S. Kamel-Reid, X. Liu, K. Siminovitch, H.A. Messner, and J.H. Lipton Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia Clin. Cancer Res. 15 2009 4750 4758
147. K.M. King, V.L. Damaraju, M.F. Vickers, S.Y. Yao, T. Lang, T.E. Tackaberry, D.A. Mowles, A.M. Ng, J.D. Young, and C.E. Cass A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems Mol. Pharmacol. 69 2006 346 353
148. M. Kinoshita, and M. Miyata Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci Hepatology 36 2002 433 438
149. Y. Kitamura, M. Hirouchi, H. Kusuhara, J.D. Schuetz, and Y. Sugiyama Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3) J. Pharmacol. Exp. Ther. 327 2008 465 473
150. K. Kiyotani, T. Mushiroda, M. Kubo, H. Zembutsu, Y. Sugiyama, and Y. Nakamura Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia Cancer Sci. 99 2008 967 972
151. Y. Kobayashi, N. Ohshiro, R. Sakai, M. Ohbayashi, N. Kohyama, and T. Yamamoto Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]) J. Pharm. Pharmacol. 57 2005 573 578
152. D. Kolwankar, D.D. Glover, J.A. Ware, and T.S. Tracy Expression and function of ABCB1 and ABCG2 in human placental tissue Drug Metab. Dispos. 33 2005 524 529
153. P. Krishnamurthy, M. Schwab, K. Takenaka, D. Nachagari, J. Morgan, M. Leslie, W. Du, K. Boyd, M. Cheok, H. Nakauchi, C. Marzolini, R.B. Kim, B. Poonkuzhali, E. Schuetz, W. Evans, M. Relling, and J.D. Schuetz Transporter-mediated protection against thiopurine-induced hematopoietic toxicity Cancer Res. 68 2008 4983 4989
154. Y.H. Kuang, T. Shen, X. Chen, K. Sodani, E. Hopper-Borge, A.K. Tiwari, J.W. Lee, L.W. Fu, and Z.S. Chen Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance Biochem. Pharmacol. 79 2010 154 161
155. A. Kuhne, M.V. Tzvetkov, Y. Hagos, H. Lage, G. Burckhardt, and J. Brockmoller Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines Biochem. Pharmacol. 78 2009 45 53
156. J.S. Lagas, L. Fan, E. Wagenaar, M.L. Vlaming, O. van Tellingen, J.H. Beijnen, and A.H. Schinkel P-glycoprotein (P-gp/Abcb1) Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin. Cancer Res. 16 2010 130 140
157. J.S. Lagas, M.L. Vlaming, O. van Tellingen, E. Wagenaar, R.S. Jansen, H. Rosing, J.H. Beijnen, and A.H. Schinkel Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics Clin. Cancer Res. 12 2006 6125 6132
158. C.S. Lancaster, C. Hu, R.M. Franke, K.K. Filipski, S.J. Orwick, Z. Chen, Z. Zuo, W.J. Loos, and A. Sparreboom Cisplatin-induced downregulation of OCTN2 affects carnitine wasting Clin. Cancer Res. 16 2010 4789 4799
159. C.A. Larson, B.G. Blair, R. Safaei, and S.B. Howell The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs Mol. Pharmacol. 75 2009 324 330
160. R.A. Larson, B.J. Druker, F. Guilhot, S.G. O'Brien, G.J. Riviere, T. Krahnke, I. Gathmann, and Y. Wang Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 111 2008 4022 4028
161. C. Laverdiere, S. Chiasson, I. Costea, A. Moghrabi, and M. Krajinovic Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia Blood. 100 2002 3832 3834
162. J. Lee, M.M. Pena, Y. Nose, and D.J. Thiele Biochemical characterization of the human copper transporter Ctr1 J. Biol. Chem. 277 2002 4380 4387
163. J. Lee, J.R. Prohaska, and D.J. Thiele Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development Proc. Natl. Acad. Sci. U. S. A. 98 2001 6842 6847
164. A.S. Levy, H.N. Sather, P.G. Steinherz, R. Sowers, M. La, J.A. Moscow, P.S. Gaynon, F.M. Uckun, J.R. Bertino, and R. Gorlick Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study J. Pediatr. Hematol. Oncol. 25 2003 688 695
165. S. Li, Y. Chen, S. Zhang, S.S. More, X. Huang, and K.M. Giacomini Role of organic cation transporter 1 OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm. Res. 28 2011 610 625
166. X.J. Liang, D.W. Shen, and M.M. Gottesman A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells J. Inorg. Biochem. 98 2004 1599 1606
167. B. Liegl, I. Kepten, C. Le, M. Zhu, G.D. Demetri, M.C. Heinrich, C.D. Fletcher, C.L. Corless, and J.A. Fletcher Heterogeneity of kinase inhibitor resistance mechanisms in GIST J. Pathol. 216 2008 64 74
168. J. Lin, D.A. Raoof, D.G. Thomas, J.K. Greenson, T.J. Giordano, G.S. Robinson, M.J. Bourner, C.T. Bauer, M.B. Orringer, and D.G. Beer L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma Neoplasia 6 2004 74 84
169. A.C. Lockhart, E. Harris, B.J. Lafleur, N.B. Merchant, M.K. Washington, M.B. Resnick, T.J. Yeatman, and W. Lee Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome Clin. Exp. Gastroenterol. 1 2008 1 7
170. W.D. Lotspeich Kidney, water and electrolyte metabolism Annu. Rev. Physiol. 20 1958 339 376
171. K.S. Lovejoy, R.C. Todd, S. Zhang, M.S. McCormick, J.A. D'Aquino, J.T. Reardon, A. Sancar, K.M. Giacomini, and S.J. Lippard cis-Diammine(pyridine) chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects Proc. Natl. Acad. Sci. U. S. A. 105 2008 8902 8907
172. F.R. Luo, P.V. Paranjpe, A. Guo, E. Rubin, and P. Sinko Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1 Drug Metab. Dispos. 30 2002 763 770
173. N.B. Lydon, and B.J. Druker Lessons learned from the development of imatinib Leuk. Res. 28 Suppl 1 2004 S29 S38
174. D.H. Mahoney Jr., J. Shuster, R. Nitschke, S.J. Lauer, N. Winick, C.P. Steuber, and B. Camitta Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial J. Clin. Oncol. 16 1998 246 254
175. E.B. Maryon, J. Zhang, J.W. Jellison, and J.H. Kaplan Human copper transporter 1 lacking O-linked glycosylation is proteolytically cleaved in a Rab9-positive endosomal compartment J. Biol. Chem. 284 2009 28104 28114
176. E. Masson, M.V. Relling, T.W. Synold, Q. Liu, J.D. Schuetz, J.T. Sandlund, C.H. Pui, and W.E. Evans Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate J. Clin. Invest. 97 1996 73 80
177. S. Masuda, T. Terada, A. Yonezawa, Y. Tanihara, K. Kishimoto, T. Katsura, O. Ogawa, and K. Inui Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2 J. Am. Soc. Nephrol. 17 2006 2127 2135
178. J.F. Mata, J.M. Garcia-Manteiga, M.P. Lostao, S. Fernandez-Veledo, E. Guillen-Gomez, I.M. Larrayoz, J. Lloberas, F.J. Casado, and M. Pastor-Anglada Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug Mol. Pharmacol. 59 2001 1542 1548
179. Y. Matloub, B.C. Bostrom, S.P. Hunger, L.C. Stork, A. Angiolillo, H. Sather, M. La, J.M. Gastier-Foster, N.A. Heerema, S. Sailer, P.J. Buckley, B. Thomson, C. Cole, J.B. Nachman, G. Reaman, N. Winick, W.L. Carroll, M. Devidas, and P.S. Gaynon Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group Blood 118 2011 243 251
180. S. Matsumoto, T. Tanaka, H. Kurokawa, K. Matsuno, Y. Hayashida, and T. Takahashi Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin Anticancer Res. 27 2007 2209 2216
181. S. Matsumoto, K. Yoshida, N. Ishiguro, T. Maeda, and I. Tamai Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(S)-9-dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride] J. Pharmacol. Exp. Ther. 322 2007 1246 1252
182. S.R. McWhinney, R.M. Goldberg, and H.L. McLeod Platinum neurotoxicity pharmacogenetics Mol. Cancer Ther. 8 2009 10 16
183. H.E. Meyer zu Schwabedissen, C. Verstuyft, H.K. Kroemer, L. Becquemont, and R.B. Kim Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms Am. J. Physiol. Renal Physiol. 298 2010 F997 F1005
184. T. Mikkaichi, T. Suzuki, T. Onogawa, M. Tanemoto, H. Mizutamari, M. Okada, T. Chaki, S. Masuda, T. Tokui, N. Eto, M. Abe, F. Satoh, M. Unno, T. Hishinuma, K. Inui, S. Ito, J. Goto, and T. Abe Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney Proc. Natl. Acad. Sci. U. S. A. 101 2004 3569 3574
185. T.S. Mikkelsen, A. Sparreboom, C. Cheng, Y. Zhou, J.M. Boyett, S.C. Raimondi, J.C. Panetta, W.P. Bowman, J.T. Sandlund, C.H. Pui, M.V. Relling, and W.E. Evans Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial J. Clin. Oncol. 29 2011 1771 1778
186. T. Minematsu, and K.M. Giacomini Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins Mol. Cancer Ther. 10 2011 531 539
187. O. Mir, S. Ropert, A. Babinet, J. Alexandre, F. Larousserie, J.P. Durand, E. Enkaoua, P. Anract, and F. Goldwasser Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma Cancer Chemother. Pharmacol. 66 2010 1059 1063
188. M. Mishima, G. Samimi, A. Kondo, X. Lin, and S.B. Howell The cellular pharmacology of oxaliplatin resistance Eur. J. Cancer 38 2002 1405 1412
189. P.J. Mishra, R. Humeniuk, G.S. Longo-Sorbello, D. Banerjee, and J.R. Bertino A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance Proc. Natl. Acad. Sci. U. S. A. 104 2007 13513 13518
190. S.S. More, O. Akil, A.G. Ianculescu, E.G. Geier, L.R. Lustig, and K.M. Giacomini Role of the copper transporter CTR1, in platinum-induced ototoxicity. J. Neurosci. 30 2010 9500 9509
191. S.S. More, M. Itsara, X. Yang, E.G. Geier, M.K. Tadano, Y. Seo, H.F. Vanbrocklin, W.A. Weiss, S. Mueller, D.A. Haas-Kogan, S.G. Dubois, K.K. Matthay, and K.M. Giacomini Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems Clin. Cancer Res. 17 2011 2339 2349
192. S.S. More, S. Li, S.W. Yee, L. Chen, Z. Xu, D.M. Jablons, and K.M. Giacomini Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue Mol. Cancer Ther. 9 2010 1058 1069
193. S. Mori, S. Ohtsuki, H. Takanaga, T. Kikkawa, Y.S. Kang, and T. Terasaki Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs J. Neurochem. 90 2004 931 941
194. H. Motohashi, Y. Sakurai, H. Saito, S. Masuda, Y. Urakami, M. Goto, A. Fukatsu, O. Ogawa, and K. Inui Gene expression levels and immunolocalization of organic ion transporters in the human kidney J. Am. Soc. Nephrol. 13 2002 866 874
195. K. Nagai, K. Nagasawa, Y. Kihara, H. Okuda, and S. Fujimoto Anticancer nucleobase analogues 6-mercaptopurine and 6-thioguanine are novel substrates for equilibrative nucleoside transporter 2 Int. J. Pharm. 333 2007 56 61
196. T. Nakamura, A. Yonezawa, S. Hashimoto, T. Katsura, and K. Inui Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity Biochem. Pharmacol. 80 2010 1762 1767
197. K. Nakatomi, M. Yoshikawa, M. Oka, Y. Ikegami, S. Hayasaka, K. Sano, K. Shiozawa, S. Kawabata, H. Soda, T. Ishikawa, S. Tanabe, and S. Kohno Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells Biochem. Biophys. Res. Commun. 288 2001 827 832
198. J.A. Nelson, G. Santos, and B.H. Herbert Mechanisms for the renal secretion of cisplatin Cancer Treat. Rep. 68 1984 849 853
199. Z. Ni, Z. Bikadi, M.F. Rosenberg, and Q. Mao Structure and function of the human breast cancer resistance protein (BCRP/ABCG2) Curr. Drug Metab. 11 2010 603 617
200. C. Nichols, and C. Kollmannsberger First-line chemotherapy of disseminated germ cell tumors Hematol. Oncol. Clin. North Am. 25, 543-556, viii 2011
201. M. Niemi, M.K. Pasanen, and P.J. Neuvonen Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake Pharmacol. Rev. 63 2011 157 181
202. A.T. Nies, H. Koepsell, K. Damme, and M. Schwab Organic cation transporters (OCTs MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol. 2011 105 167
203. P. Noordhuis, A.C. Laan, K. van de Born, N. Losekoot, I. Kathmann, and G.J. Peters Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines Biochem. Pharmacol. 76 2008 53 61
204. M.D. Norris, J. Smith, K. Tanabe, P. Tobin, C. Flemming, G.L. Scheffer, P. Wielinga, S.L. Cohn, W.B. London, G.M. Marshall, J.D. Allen, and M. Haber Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro Mol. Cancer Ther. 4 2005 547 553
205. Y. Nose, E.M. Rees, and D.J. Thiele Structure of the Ctr1 copper trans'PORE'ter reveals novel architecture Trends Biochem. Sci. 31 2006 604 607
206. T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, and I. Tamai Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms Drug Metab. Dispos. 33 2005 434 439
207. S.G. O'Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J.J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J.L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J.M. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A.E. Bolton, R. Capdeville, and B.J. Druker Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N. Engl. J. Med. 348 2003 994 1004
208. K.Y. Ohta, K. Inoue, T. Yasujima, M. Ishimaru, and H. Yuasa Functional characteristics of two human MATE transporters: kinetics of cimetidine transport and profiles of inhibition by various compounds J. Pharm. Pharm. Sci. 12 2009 388 396
209. M. Okabe, G. Szakacs, M.A. Reimers, T. Suzuki, M.D. Hall, T. Abe, J.N. Weinstein, and M.M. Gottesman Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters Mol. Cancer Ther. 7 2008 3081 3091
210. M. Okabe, M. Unno, H. Harigae, M. Kaku, Y. Okitsu, T. Sasaki, T. Mizoi, K. Shiiba, H. Takanaga, T. Terasaki, S. Matsuno, I. Sasaki, S. Ito, and T. Abe Characterization of the organic cation transporter SLC22A16: a doxorubicin importer Biochem. Biophys. Res. Commun. 333 2005 754 762
211. S. Oswald, A. Nassif, C. Modess, M. Keiser, U. Hanke, A. Engel, D. Lutjohann, W. Weitschies, and W. Siegmund Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers Clin. Pharmacol. Ther. 87 2010 663 667
212. M. Otsuka, T. Matsumoto, R. Morimoto, S. Arioka, H. Omote, and Y. Moriyama A human transporter protein that mediates the final excretion step for toxic organic cations Proc. Natl. Acad. Sci. U. S. A. 102 2005 17923 17928
213. S. Owatari, S. Akune, M. Komatsu, R. Ikeda, S.D. Firth, X.F. Che, M. Yamamoto, K. Tsujikawa, M. Kitazono, T. Ishizawa, T. Takeuchi, T. Aikou, J.F. Mercer, S. Akiyama, and T. Furukawa Copper-transporting P-type ATPase ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 67 2007 4860 4868
214. R.P. Owen, I. Badagnani, and K.M. Giacomini Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter CNT2. J. Biol. Chem. 281 2006 26675 26682
215. M.F. Paine, L.Y. Leung, and P.B. Watkins New insights into drug absorption: studies with sirolimus Ther. Drug Monit. 26 2004 463 467
216. B.F. Pan, D.H. Sweet, J.B. Pritchard, R. Chen, and J.A. Nelson A transfected cell model for the renal toxin transporter, rOCT2 Toxicological sciences: an official journal of the Society of Toxicology 47 1999 181 186
217. G. Pan, and W.F. Elmquist Mitoxantrone permeability in MDCKII cells is influenced by active influx transport Mol Pharm. 4 2007 475 483
218. I. Park, M.H. Ryu, S.J. Sym, S.S. Lee, G. Jang, T.W. Kim, H.M. Chang, J.L. Lee, H. Lee, and Y.K. Kang Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor Jpn. J. Clin. Oncol. 39 2009 105 110
219. A. Patino-Garcia, M. Zalacain, L. Marrodan, M. San-Julian, and L. Sierrasesumaga Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression J. Pediatr. 154 2009 688 693
220. K. Paulsson, E. Forestier, H. Lilljebjorn, J. Heldrup, M. Behrendtz, B.D. Young, and B. Johansson Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia Proc. Natl. Acad. Sci. U. S. A. 107 2010 21719 21724
221. B. Peng, C. Dutreix, G. Mehring, M.J. Hayes, M. Ben-Am, M. Seiberling, R. Pokorny, R. Capdeville, and P. Lloyd Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion J. Clin. Pharmacol. 44 2004 158 162
222. M.J. Petris, K. Smith, J. Lee, and D.J. Thiele Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1 J. Biol. Chem. 278 2003 9639 9646
223. S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint, M.A. Bernard, R. Lassalle, G. Marit, J. Reiffers, B. Begaud, N. Moore, M. Molimard, and F.X. Mahon Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood 109 2007 3496 3499
224. J.W. Polli, J.E. Humphreys, K.A. Harmon, S. Castellino, M.J. O'Mara, K.L. Olson, L.S. John-Williams, K.M. Koch, and C.J. Serabjit-Singh The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6- [5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions Drug Metab. Dispos. 36 2008 695 701
225. J.W. Polli, K.L. Olson, J.P. Chism, L.S. John-Williams, R.L. Yeager, S.M. Woodard, V. Otto, S. Castellino, and V.E. Demby An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) Drug Metab. Dispos. 37 2009 439 442
226. A. Qiu, M. Jansen, A. Sakaris, S.H. Min, S. Chattopadhyay, E. Tsai, C. Sandoval, R. Zhao, M.H. Akabas, and I.D. Goldman Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption Cell. 127 2006 917 928
227. D. Raghavan Testicular cancer: maintaining the high cure rate Oncology. 17, 218-228; discussion 228-219, 234-215, passim 2003
228. A. Rajeswaran, A. Trojan, B. Burnand, and M. Giannelli Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials Lung Cancer. 59 2008 1 11
229. A. Rajgopal, E.E. Sierra, R. Zhao, and I.D. Goldman Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities Am. J. Physiol. Cell Physiol. 281 2001 C1579 C1586
230. T. Rau, B. Erney, R. Gores, T. Eschenhagen, J. Beck, and T. Langer High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations Clin. Pharmacol. Ther. 80 2006 468 476
231. E. Raymond, S.G. Chaney, A. Taamma, and E. Cvitkovic Oxaliplatin: a review of preclinical and clinical studies Ann. Oncol. 9 1998 1053 1071
232. E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and molecular pharmacology of oxaliplatin Mol. Cancer Ther. 1 2002 227 235
233. M.V. Relling, C.H. Pui, J.T. Sandlund, G.K. Rivera, M.L. Hancock, J.M. Boyett, E.G. Schuetz, and W.E. Evans Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia Lancet. 356 2000 285 290
234. O. Rixe, W. Ortuzar, M. Alvarez, R. Parker, E. Reed, K. Paull, and T. Fojo Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel Biochem. Pharmacol. 52 1996 1855 1865
235. L. Rothem, I. Ifergan, Y. Kaufman, D.G. Priest, G. Jansen, and Y.G. Assaraf Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines Biochem. J. 367 2002 741 750
236. R. Safaei, S. Otani, B.J. Larson, M.L. Rasmussen, and S.B. Howell Transport of cisplatin by the copper efflux transporter ATP7B Mol. Pharmacol. 73 2008 461 468
237. K. Sai, N. Kaniwa, M. Itoda, Y. Saito, R. Hasegawa, K. Komamura, K. Ueno, S. Kamakura, M. Kitakaze, K. Shirao, H. Minami, A. Ohtsu, T. Yoshida, N. Saijo, Y. Kitamura, N. Kamatani, S. Ozawa, and J. Sawada Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan Pharmacogenetics. 13 2003 741 757
238. K. Sai, Y. Saito, K. Maekawa, S.R. Kim, N. Kaniwa, T. Nishimaki-Mogami, J. Sawada, K. Shirao, T. Hamaguchi, N. Yamamoto, H. Kunitoh, Y. Ohe, Y. Yamada, T. Tamura, T. Yoshida, Y. Matsumura, A. Ohtsu, N. Saijo, and H. Minami Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients Cancer Chemother. Pharmacol. 66 2010 95 105
239. M.H. Saier Jr. Tracing pathways of transport protein evolution Mol. Microbiol. 48 2003 1145 1156
240. G. Samimi, R. Safaei, K. Katano, A.K. Holzer, M. Rochdi, M. Tomioka, M. Goodman, and S.B. Howell Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells Clin. Cancer Res. 10 2004 4661 4669
241. N. Savaraj, C. Wu, M. Wangpaichitr, M.T. Kuo, T. Lampidis, C. Robles, A.J. Furst, and L. Feun Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine Int. J. Oncol. 23 2003 173 179
242. P.J. Schuler, S. Trellakis, J. Greve, M. Bas, C. Bergmann, E. Bolke, G. Lehnerdt, S. Mattheis, A.E. Albers, S. Brandau, S. Lang, T.L. Whiteside, H. Bier, and T.K. Hoffmann In vitro chemosensitivity of head and neck cancer cell lines Eur. J. Med. Res. 15 2010 337 344
243. U.I. Schwarz, H.E. Meyer zu Schwabedissen, R.G. Tirona, A. Suzuki, B.F. Leake, Y. Mokrab, K. Mizuguchi, R.H. Ho, and R.B. Kim Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity Pharmacogenet. Genomics. 21 2011 103 114
244. T. Sekine, N. Watanabe, M. Hosoyamada, Y. Kanai, and H. Endou Expression cloning and characterization of a novel multispecific organic anion transporter J. Biol. Chem. 272 1997 18526 18529
245. M.D. Shelley, A. Cleves, T.J. Wilt, and M.D. Mason Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma BJU Int. 108 2011 168 179
246. D.W. Shen, S. Goldenberg, I. Pastan, and M.M. Gottesman Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake J. Cell. Physiol. 183 2000 108 116
247. F. Shen, B.J. Bailey, S. Chu, A.K. Bence, X. Xue, P. Erickson, A.R. Safa, W.T. Beck, and L.C. Erickson Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells J. Pharmacol. Exp. Ther. 330 2009 423 429
248. H. Shen, F.Y. Lee, and J. Gan Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2) J. Pharmacol. Exp. Ther. 337 2011 423 432
249. J. Shigeta, K. Katayama, J. Mitsuhashi, K. Noguchi, and Y. Sugimoto BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization Cancer Sci. 101 2010 1813 1821
250. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
251. N.F. Smith, M.R. Acharya, N. Desai, W.D. Figg, and A. Sparreboom Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel Cancer Biol. Ther. 4 2005 815 818
252. N.F. Smith, W.D. Figg, and A. Sparreboom Pharmacogenetics of irinotecan metabolism and transport: an update Toxicol. In Vitro. 20 2006 163 175
253. N.F. Smith, S. Marsh, T.J. Scott-Horton, A. Hamada, S. Mielke, K. Mross, W.D. Figg, J. Verweij, H.L. McLeod, and A. Sparreboom Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics Clin. Pharmacol. Ther. 81 2007 76 82
254. R. Sowers, B.D. Wenzel, C. Richardson, P.A. Meyers, J.H. Healey, A.S. Levy, and R. Gorlick Impairment of methotrexate transport is common in osteosarcoma tumor samples Sarcoma. 2011 2011 834170
255. A. Sparreboom, R.M. Franke, and S.D. Baker Reply to J Gligorov et al. J. Clin. Oncol. May 20 2011 e456 e457
256. Sugiyama, Y., Kato, Y. and Chu, X., 1998. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother. Pharmacol. 42 Suppl, S44-49.
257. M. Svoboda, K. Wlcek, B. Taferner, S. Hering, B. Stieger, D. Tong, R. Zeillinger, T. Thalhammer, and W. Jager Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: Relevance for paclitaxel transport Biomed. Pharmacother. 65 2011 417 426
258. D.H. Sweet, N.A. Wolff, and J.B. Pritchard Expression cloning and characterization of ROAT1 The basolateral organic anion transporter in rat kidney. J. Biol. Chem. 272 1997 30088 30095
259. T.W. Synold, M.V. Relling, J.M. Boyett, G.K. Rivera, J.T. Sandlund, H. Mahmoud, W.M. Crist, C.H. Pui, and W.E. Evans Blast cell methotrexate- polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia J. Clin. Invest. 94 1994 1996 2001
260. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234
261. Z. Szakacs, S. Beni, Z. Varga, L. Orfi, G. Keri, and B. Noszal Acid-base profiling of imatinib (gleevec) and its fragments J. Med. Chem. 48 2005 249 255
262. M. Tagen, Y. Zhuang, F. Zhang, K.E. Harstead, J. Shen, P. Schaiquevich, C.H. Fraga, J.C. Panetta, C.M. Waters, and C.F. Stewart P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice Drug Metab. Lett. 4 2010 195 201
263. N. Takahashi, M. Miura, S.A. Scott, H. Kagaya, Y. Kameoka, H. Tagawa, H. Saitoh, N. Fujishima, T. Yoshioka, M. Hirokawa, and K. Sawada Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia J. Hum. Genet. 55 2010 731 737
264. T. Takahata, K. Ookawa, K. Suto, M. Tanaka, H. Yano, O. Nakashima, M. Kojiro, Y. Tamura, T. Tateishi, Y. Sakata, and S. Fukuda Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines Basic Clin. Pharmacol. Toxicol. 102 2008 399 407
265. M. Takano, K. Inui, T. Okano, H. Saito, and R. Hori Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles Biochim. Biophys. Acta. 773 1984 113 124
266. M. Takano, Y. Otani, M. Tanda, M. Kawami, J. Nagai, and R. Yumoto Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line HepG2. Drug Metab. Pharmacokinet. 24 2009 418 427
267. Tamai, I., 2011. Oral drug delivery utilizing intestinal OATP transporters. Adv.Drug Deliv. Rev.
268. I. Tamai, R. Ohashi, J. Nezu, H. Yabuuchi, A. Oku, M. Shimane, Y. Sai, and A. Tsuji Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2 J. Biol. Chem. 273 1998 20378 20382
269. S.C. Tang, J.S. Lagas, N.A. Lankheet, B. Poller, M.J. Hillebrand, H. Rosing, J.H. Beijnen, and A.H. Schinkel Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration Int. J. Cancer 130 2012 223 233
270. Y. Tanihara, S. Masuda, T. Katsura, and K. Inui Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2 Biochem. Pharmacol. 78 2009 1263 1271
271. Y. Tanihara, S. Masuda, T. Sato, T. Katsura, O. Ogawa, and K. Inui Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters Biochem. Pharmacol. 74 2007 359 371
272. T. Tanino, A. Nawa, M. Nakao, M. Noda, S. Fujiwara, and M. Iwaki Organic anion transporting polypeptide 2-mediated uptake of paclitaxel and 2'-ethylcarbonate-linked paclitaxel in freshly isolated rat hepatocytes J. Pharm. Pharmacol. 61 2009 1029 1035
273. W.A. Teft, S.E. Mansell, and R.B. Kim Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1) Drug Metab. Dispos. 39 2011 558 562
274. T. Terada, and K. Inui Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A) Biochem. Pharmacol. 75 2008 1689 1696
275. J. Thomas, L. Wang, R.E. Clark, and M. Pirmohamed Active transport of imatinib into and out of cells: implications for drug resistance Blood. 104 2004 3739 3745
276. Q. Tian, J. Zhang, S.Y. Chan, T.M. Tan, W. Duan, M. Huang, Y.Z. Zhu, E. Chan, Q. Yu, Y.Q. Nie, P.C. Ho, Q. Li, K.Y. Ng, H.Y. Yang, H. Wei, J.S. Bian, and S.F. Zhou Topotecan is a substrate for multidrug resistance associated protein 4 Curr. Drug Metab. 7 2006 105 118
277. Q. Tian, J. Zhang, T.M. Tan, E. Chan, W. Duan, S.Y. Chan, U.A. Boelsterli, P.C. Ho, H. Yang, J.S. Bian, M. Huang, Y.Z. Zhu, W. Xiong, X. Li, and S. Zhou Human multidrug resistance associated protein 4 confers resistance to camptothecins Pharm. Res. 22 2005 1837 1853
278. J.S. Tobias, K. Monson, N. Gupta, H. Macdougall, J. Glaholm, I. Hutchison, L. Kadalayil, and A. Hackshaw Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial Lancet Oncol. 11 2010 66 74
279. L.R. Trevino, N. Shimasaki, W. Yang, J.C. Panetta, C. Cheng, D. Pei, D. Chan, A. Sparreboom, K.M. Giacomini, C.H. Pui, W.E. Evans, and M.V. Relling Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects J. Clin. Oncol. 27 2009 5972 5978
280. M. Tsuda, T. Terada, M. Ueba, T. Sato, S. Masuda, T. Katsura, and K. Inui Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells J. Pharmacol. Exp. Ther. 329 2009 185 191
281. T. Umemoto, Y. Kobayashi, M. Suzuki, Y. Sanada, and T. Yamamoto Cloning and pharmacological characterization of a novel gene encoding human nucleoside transporter 1 (hNT1) from a human breast cancer cDNA library Life Sci. 84 2009 45 51
282. E.S. Unal, R. Zhao, and I.D. Goldman Role of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1 Am. J. Physiol. Cell Physiol. 297 2009 C66 C74
283. Y. Uwai, R. Taniguchi, H. Motohashi, H. Saito, M. Okuda, and K. Inui Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3 Drug Metab. Pharmacokinet. 19 2004 369 374
284. R.A. van Aubel, P.H. Smeets, J.G. Peters, R.J. Bindels, and F.G. Russel The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP J. Am. Soc. Nephrol. 13 2002 595 603
285. E. van de Steeg, C.M. van der Kruijssen, E. Wagenaar, J.E. Burggraaff, E. Mesman, K.E. Kenworthy, and A.H. Schinkel Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1) Drug Metab. Dispos. 37 2009 277 281
286. E. van de Steeg, A. van Esch, E. Wagenaar, C.M. van der Kruijssen, O. van Tellingen, K.E. Kenworthy, and A.H. Schinkel High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel Clin. Cancer Res. 17 2011 294 301
287. A.T. van Oosterom, I. Judson, J. Verweij, S. Stroobants, E. Donato di Paola, S. Dimitrijevic, M. Martens, A. Webb, R. Sciot, M. Van Glabbeke, S. Silberman, and O.S. Nielsen Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 2001 1421 1423
288. R.A. van Waterschoot, J.S. Lagas, E. Wagenaar, H. Rosing, J.H. Beijnen, and A.H. Schinkel Individual and combined roles of CYP3A P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int. J. Cancer. 127 2010 2959 2964
289. L.J. Van Winkle Biomembrane transport 1999 Academic Press San Diego
290. A.L. VanWert, and D.H. Sweet Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates Pharm. Res. 25 2008 453 462
291. S.R. Vavricka, D. Jung, M. Fried, U. Grutzner, P.J. Meier, and G.A. Kullak-Ublick The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma J. Hepatol. 40 2004 212 218
292. J. Verweij, P.G. Casali, J. Zalcberg, A. LeCesne, P. Reichardt, J.Y. Blay, R. Issels, A. van Oosterom, P.C. Hogendoorn, M. Van Glabbeke, R. Bertulli, and I. Judson Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet. 364 2004 1127 1134
293. M.L. Vlaming, K. Mohrmann, E. Wagenaar, D.R. de Waart, R.P. Elferink, J.S. Lagas, O. van Tellingen, L.D. Vainchtein, H. Rosing, J.H. Beijnen, J.H. Schellens, and A.H. Schinkel Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice J. Pharmacol. Exp. Ther. 318 2006 319 327
294. M.L. Vlaming, Z. Pala, A. van Esch, E. Wagenaar, D.R. de Waart, K. van de Wetering, C.M. van der Kruijssen, R.P. Oude Elferink, O. van Tellingen, and A.H. Schinkel Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo Clin. Cancer Res. 15 2009 3084 3093
295. M.L. Vlaming, Z. Pala, A. van Esch, E. Wagenaar, O. van Tellingen, D.R. de Waart, R.P. Oude Elferink, K. van de Wetering, and A.H. Schinkel Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate Clin. Cancer Res. 14 2008 8152 8160
296. M.L. Vlaming, A. van Esch, Z. Pala, E. Wagenaar, K. van de Wetering, O. van Tellingen, and A.H. Schinkel Abcc2 (Mrp2) Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol. Cancer Ther. 8 2009 3350 3359
297. A.L. Walker, R.M. Franke, A. Sparreboom, and R.E. Ware Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters Exp. Hematol. 39 2011 446 456
298. L. Wang, A. Giannoudis, S. Lane, P. Williamson, M. Pirmohamed, and R.E. Clark Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia Clin. Pharmacol. Ther. 83 2008 258 264
299. Y. Wang, R. Zhao, and I.D. Goldman Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier Clin. Cancer Res. 10 2004 6256 6264
300. J.R. Whetstine, R.M. Flatley, and L.H. Matherly The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter Biochem. J. 367 2002 629 640
301. D.L. White, V.A. Saunders, P. Dang, J. Engler, A. Venables, S. Zrim, A. Zannettino, K. Lynch, P.W. Manley, and T. Hughes Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Blood. 110 2007 4064 4072
302. D.L. White, V.A. Saunders, P. Dang, J. Engler, A.C. Zannettino, A.C. Cambareri, S.R. Quinn, P.W. Manley, and T.P. Hughes OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Blood 108 2006 697 704
303. N. Widmer, L.A. Decosterd, C. Csajka, M. Montemurro, A. Haouala, S. Leyvraz, and T. Buclin Imatinib plasma levels: correlation with clinical benefit in GIST patients Br. J. Cancer 102 2010 1198 1199
304. J. Wijnholds, G.L. Scheffer, M. van der Valk, P. van der Valk, J.H. Beijnen, R.J. Scheper, and P. Borst Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage J. Exp. Med. 188 1998 797 808
305. F.M. Williams, and W.F. Flintoff Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake J. Biol. Chem. 270 1995 2987 2992
306. H. Yamaguchi, M. Kobayashi, M. Okada, T. Takeuchi, M. Unno, T. Abe, J. Goto, T. Hishinuma, and N. Mano Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes Cancer Lett. 260 2008 163 169
307. Y. Yamakawa, A. Hamada, T. Shuto, M. Yuki, T. Uchida, H. Kai, T. Kawaguchi, and H. Saito Pharmacokinetic Impact of SLCO1A2 Polymorphisms on Imatinib Disposition in Patients With Chronic Myeloid Leukemia Clin. Pharmacol. Ther. 90 2011 157 163
308. W. Yamamoto, J. Verweij, P. de Bruijn, M.J. de Jonge, H. Takano, M. Nishiyama, M. Kurihara, and A. Sparreboom Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells Anticancer. Drugs. 12 2001 419 432
309. T.L. Yang-Feng, Y.Y. Ma, R. Liang, P.D. Prasad, F.H. Leibach, and V. Ganapathy Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization Biochem. Biophys. Res. Commun. 210 1995 874 879
310. S. Yokoo, A. Yonezawa, S. Masuda, A. Fukatsu, T. Katsura, and K. Inui Differential contribution of organic cation transporters OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 74 2007 477 487
311. T. Yokooji, N. Mori, and T. Murakami Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats J. Pharm. Pharmacol. 61 2009 911 918
312. A. Yonezawa, S. Masuda, K. Nishihara, I. Yano, T. Katsura, and K. Inui Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat Biochem. Pharmacol. 70 2005 1823 1831
313. A. Yonezawa, S. Masuda, S. Yokoo, T. Katsura, and K. Inui Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family) J. Pharmacol. Exp. Ther. 319 2006 879 886
314. O. Zach, O. Krieger, M. Foedermayr, B. Zellhofer, and D. Lutz OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients Leuk. Lymphoma 49 2008 2222 2223
315. J.R. Zalcberg, J. Verweij, P.G. Casali, A. Le Cesne, P. Reichardt, J.Y. Blay, M. Schlemmer, M. Van Glabbeke, M. Brown, and I.R. Judson Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg Eur. J. Cancer 41 2005 1751 1757
316. S. Zhang, K.S. Lovejoy, J.E. Shima, L.L. Lagpacan, Y. Shu, A. Lapuk, Y. Chen, T. Komori, J.W. Gray, X. Chen, S.J. Lippard, and K.M. Giacomini Organic cation transporters are determinants of oxaliplatin cytotoxicity Cancer Res. 66 2006 8847 8857
317. Y.H. Zhang, Q. Wu, X.Y. Xiao, D.W. Li, and X.P. Wang Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell Cancer Lett. 291 2010 76 82
318. R. Zhao, F. Gao, and I.D. Goldman Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells Am. J. Physiol. Cell Physiol. 282 2002 C1512 C1517
319. R. Zhao, F. Gao, Y. Wang, G.A. Diaz, B.D. Gelb, and I.D. Goldman Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells J. Biol. Chem. 276 2001 1114 1118
320. R. Zhao, L.H. Matherly, and I.D. Goldman Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues Expert Rev. Mol. Med. 11 2009 e4
321. R. Zhao, S.H. Min, Y. Wang, E. Campanella, P.S. Low, and I.D. Goldman A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis J. Biol. Chem. 284 2009 4267 4274
322. R. Zhao, A. Qiu, E. Tsai, M. Jansen, M.H. Akabas, and I.D. Goldman The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier Mol. Pharmacol. 74 2008 854 862
323. R. Zhao, R.G. Russell, Y. Wang, L. Liu, F. Gao, B. Kneitz, W. Edelmann, and I.D. Goldman Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs J. Biol. Chem. 276 2001 10224 10228
324. B. Zhou, and J. Gitschier hCTR1: a human gene for copper uptake identified by complementation in yeast Proc. Natl. Acad. Sci. U. S. A. 94 1997 7481 7486
325. Y. Zhuang, C.H. Fraga, K.E. Hubbard, N. Hagedorn, J.C. Panetta, C.M. Waters, and C.F. Stewart Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor Cancer Res. 66 2006 11305 11313
326. J. Zisowsky, S. Koegel, S. Leyers, K. Devarakonda, M.U. Kassack, M. Osmak, and U. Jaehde Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells Biochem. Pharmacol. 73 2007 298 307
327. O. Zolk, and M.F. Fromm Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions Clin. Pharmacol. Ther. 89 2011 798 805
328. G. Zollner, M. Wagner, P. Fickert, D. Silbert, A. Fuchsbichler, K. Zatloukal, H. Denk, and M. Trauner Hepatobiliary transporter expression in human hepatocellular carcinoma Liver Int. 25 2005 367 379
329. L.A. Zwelling, and K.W. Kohn Mechanism of action of cis- dichlorodiammineplatinum(II) Cancer Treat. Rep. 63 1979 1439 1444